Outcomes of non-metastatic HER-2 positive breast cancer before and after the introduction of anti-HER-2 therapy: a retrospective study from a tertiary Egyptian center

Background

HER-2 positive breast cancer accounts for 15-20% of cases and is associated with aggressive behavior and poor prognosis. Anti-HER-2 therapy, including trastuzumab and pertuzumab, has improved outcomes in Western populations; however, real-world data in Egyptian patients remain limited. This study evaluated pathological response, disease-free survival (DFS), and overall survival (OS) among Egyptian patients with non-metastatic HER-2 positive breast cancer treated before and after the introduction of anti-HER-2 therapy.